4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $189,171.75 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 15,725 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $12.03, for a total value of $189,171.75. Following the transaction, the insider directly owned 884,152 shares in the company, valued at $10,636,348.56. This trade represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

David Kirn also recently made the following trade(s):

• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.87, for a total value of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $19,258.44.

4D Molecular Therapeutics Stock Performance

FDMT traded up $0.40 on Tuesday, hitting $11.70. 651,784 shares of the company were exchanged, compared to its average volume of 817,839. The firm has a fifty day simple moving average of $10.26 and a two-hundred day simple moving average of $9.36. The stock has a market capitalization of $611.68 million, a PE ratio of -4.55 and a beta of 2.70. 4D Molecular Therapeutics, Inc. has a 12 month low of $4.11 and a 12 month high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. On average, equities analysts expect that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current year.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new stake in 4D Molecular Therapeutics in the first quarter valued at $46,000. Millennium Management LLC increased its position in 4D Molecular Therapeutics by 15.0% during the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after purchasing an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in 4D Molecular Therapeutics in the 1st quarter worth $39,000. American Century Companies Inc. raised its holdings in 4D Molecular Therapeutics by 11.5% in the 2nd quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock worth $181,000 after purchasing an additional 5,026 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after purchasing an additional 2,284 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on FDMT shares. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Chardan Capital reissued a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. The Goldman Sachs Group set a $33.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, May 8th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.88.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.